论文部分内容阅读
目的：观察长春瑞滨加顺铂（NP方案）治疗晚期非小细胞肺癌（NSCLC）的疗效。方法：86例晚期NSCLC患者随机分成NP方案组（46例）和丝裂霉素加长春地辛加顺铂（MVP方案）组（40例）。每例至少治疗2周期。结果：NP组和MVP组的有效率分别为41％和30％（P ＞0．05），中位缓解期分别为3．0个月和2．6个月（P ＞0．05），中位生存期分别为7．8个月和6．5个月（P ＞0．05）。主要不良反应为粒细胞缺乏症， NP组的Ⅲ、Ⅳ度的白细胞下降为61％，MVP组为30％（P ＜0．05）。结论：NP方案和MVP方案治疗晚期NSCLC疗效相近，毒性均可耐受。
Objective: To observe the efficacy of vinorelbine plus cisplatin (NP regimen) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Eighty-six patients with advanced NSCLC were randomly divided into NP group (46 cases) and mitomycin plus vinca plus cisplatin (MVP group) (40 cases). Each treatment for at least 2 cycles. Results: The effective rates of NP group and MVP group were 41% and 30% respectively (P> 0.05), and the median remission rates were 3.0 months and 2.6 months (P> 0.05) The median survival time was 7.8 months and 6.5 months (P> 0.05). The main adverse reaction was agranulocytosis. The NP, Ⅲ and Ⅳ degrees of leukopenia was 61% and MVP was 30% (P <0.05). Conclusion: The efficacy of NP and MVP in the treatment of advanced NSCLC is similar, and the toxicity can be tolerated.